News

The Status of ANT01 and ANeuroTech

FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD). The emerging clinical late stage biopharmaceutical company ANEUROTECH have – as an outcome of the FDA Pre-IND Meeting on 19JAN2021 – reached out an agreement with the FDA to continue with its submitted Pivotal Phase IIIB development program on ANT01 in the higly… Read more »

Evidence regarding the need for effective treatment of Major Depressive Disorder with associated Subjective Cognitive Decline*

*Flatt et al, Alzheimer’s Dement. 2021;7:e12197. Indicating need for effective treatment of Major Depressive Disorder with associated Subjective Cognitive Decline (MDD-SCD). Intro: AbstractIntroduction: Subjective cognitive decline (SCD) represents self-reported problems with memory, a possible early sign of dementia. Little is known about SCD among sexual and gender minority (SGM) adults who identify as lesbian, gay,… Read more »


The Status of ANT01 and ANeuroTech

23 February 2022
FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD).

Read more

Scroll to Top